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• Abnormal expression of p53/L1CAM/ER/PR is strongly correlated with higher ESMO-ESGO-ESTRO risk classification groups.
• Within the ‘high-advanced/metastatic’ risk group, abnormal expression of p53/L1CAM/ER/PR was most predictive for outcome.
• p53-abn, ER/PR- and ‘high-advanced/metastatic’ risk group were independently associated with reduced DSS.
• IHC biomarkers have important additional prognostic relevance in both patients with and without lymph node metastasis.⁎ Corresponding author at: Department of Obstetrics an
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ImmunohistochemistryObjective. Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer
(EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMO-
ESGO-ESTRO risk classification and lymph node (LN) status in EC.
Methods. Retrospective multicenter study within the European Network for Individualized Treatment of En-
dometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM),
estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status
and outcome.d Gynaecology, Radboud university medical center, Geert Grooteplein 10, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands.
. Vrede).
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Outcome
Lymph node metastasisResults. A total of 763 EC patients were includedwith a median follow-up of 5.5-years. Abnormal IHC expres-
sion was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients.
Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and
combined associatedwith the worst outcomewithin the ‘high and advanced/metastatic’ risk group. In multivar-
iate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO ‘high and advanced/metastatic’were independently asso-
ciated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node
metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable out-
come with patients without LNM and abnormal IHC expression.
Conclusion. The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the
ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/
PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorpora-
tion into the ESMO-ESGO-ESTRO risk classification.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Endometrial cancer (EC) is the most common gynecologic malig-
nancy in industrialized countries and the incidence is rising due to ad-
vanced life expectancy and obesity [1]. In general, patients diagnosed
at an early stage have a favorable prognosis. Yet, about 20% of patients
with clinical early stage disease have a poor outcome [2,3]. ECs are histo-
logically classified into type 1, comprising endometrioid EC (EEC)with a
favorable prognosis, and type 2, comprising of non-endometrioid EC
(NEEC)most commonly with serous-, carcinosarcoma- or clear cell his-
tology and unfavorable prognosis [4].
Currently used risk classifications systems are based on clinicopath-
ological risk factors, and guide primary- and/or adjuvant treatment. Dif-
ferent EC risk classifications are used in clinical practice: the European
Society for Medical Oncology - European Society of Gynaecological On-
cology -European SocieTy for Radiotherapy & Oncology (ESMO-ESGO-
ESTRO), Post-operative Radiation Therapy for Endometrial Carcinoma
(PORTEC) and Gynecologic Oncology Group (GOG) criteria [1,5–7]. All
these risk classifications stratify into ‘low, low-intermediate, intermedi-
ate, high-intermediate, high or advanced/metastatic’ based on tumor
grade, stage, histology, and age (GOG and PORTEC) [5–8]. The ESMO-
ESGO-ESTRO risk classification can be used pre-operatively to guide
the need for lymph node (LN) directed surgery, and post-operatively
to define adjuvant treatment. Recently, we published the ENDORISK
model showing improved pre-operative risk classification in EC with
easy accessible biomarkers integrated in a Bayesian network [9]. This
personalized network included immunohistochemical (IHC) expression
of p53, L1 cell-adhesionmolecule (L1CAM), estrogen receptor (ER), pro-
gesterone receptor (PR), and clinical preoperative biomarkers and was
established to predict lymph node metastasis (LNM) and outcome
pre-operatively.
The Cancer Genome Atlas (TCGA) identified four important prog-
nostic molecular subgroups based on integrated genomic data [10], in
whichpatientswith p53-abn had the poorest outcome [11–13]. Integra-
tion of molecular profiling according to the TCGA in the ESMO risk clas-
sification was evaluated by Talhouk et al. and showed high prevalence
of p53-abn in the ESMO ‘high’ risk group. Yet, for the other ESMO risk
groups molecular profiling was not discriminative [11].
The integration of molecular profiling appears promising in guiding
adjuvant treatment [14]. However, routine molecular profiling in each
patient is expensive, and as most patients have a good outcome with
hysterectomy only, a cost-effective stepwise approach might be a suit-
able alternative. It is hypothesized that the use of pre-operative IHC bio-
markers such as p53, L1CAM and ER/PR, is not only valuable in guiding
primary surgical approach (e.g. ENDORISK), yet also adjuvant treatment
in daily clinical practice. Despite their prognostic relevance for LNM and
survival in EC, none of these were studied in relation to the post-
operative ESMO-ESGO-ESTRO risk classification groups or to LN status
[13,15–19]. Therefore, our primary aim was to investigate the added
prognostic relevance of pre-operative IHC biomarkers, p53/L1CAM/ER/788PR, to the post-operative ESMO-ESGO-ESTRO risk classification groups
in EC. Secondary, the added prognostic relevance of these IHC bio-
markers to LN status in EC.
2. Materials and methods
2.1. Study cohort
Within the EuropeanNetwork for Individualized Treatment of Endo-
metrial Cancer (ENITEC), a retrospective multicenter cohort study was
performed. The patients were surgically treated between February
1995 and August 2013 at one of the 10 participating ENITEC centers
and were identified from a previously published cohort [9,20]. Only pa-
tients diagnosed by an expert gynaecological pathologist with complete
clinical and pathological data and follow-up of at least 36 months were
included, yielding 1199 patients out of ten European hospitals.
2.2. Pathological characteristics
Pre-operative tumor grade and histology were used for analysis,
combined with IHC staining of p53, L1CAM, ER and PR according to
ENDORISK [9]. Detailed information on tissue processing and IHC anal-
ysis is shown in Supplementary S1 method.
Scoring of the IHC was performed twice by assessors blinded to
pathological and clinical characteristics (N.V., H.K., J.B., K.v.d.V., C.R.).
Disagreements in scoring were solved in a consensus meeting with all
assessors. For p53, staining was considered abnormal/aberrant (p53-
abn) when more than 80% of tumor cell nuclei showed strong expres-
sion (over-expression) or when there was complete absence of nuclear
staining (null-expression). For L1CAM, the number of tumor cells show-
ingmembranous expressionwas scored and dichotomized, using 10% as
a cut-off value. For ER and PR, the number of stained tumor nuclei was
scored. Cases were also dichotomized, using 10% as a cut-off value.
L1CAM expression was considered abnormal when >10% of tumor
cells were positive (L1CAM+), ER and/or PR expressionwas considered
abnormal when <10% nuclear staining was present (ER/PR-).
2.3. Post-operative ESMO-ESGO-ESTRO risk classification
Five subgroupswere identified based on post-operative tumor stage,
tumor histology, grade, myometrial invasion (MI) and presence of
lymphovascular space invasion (LVSI): low, intermediate, high-
intermediate, high and advanced/metastatic risk group [5].
2.4. Lymph node status
For LN status three subgroups were defined: histologically con-
firmed LNM (N1), LN sampled by lymphadenectomy and histologically
negative (N0), and LN status unknown (Nx) if no lymphadenectomy
was performed. Sentinel lymph node (SLN) procedure was allowed
Table 1




Age (years) 65.2 ± 10.2
BMI (kg/m2) 29.9 ± 6.7
Pre-operative histology
Tumor grade 1–2 545 (71.4)
3 109 (14.4)
Not classified 108 (14.2)
Histology Endometrioid 682 (89.4)
Non-endometrioid 39 (5.1)
Not specified 42 (5.5)
Biomarker expression P53-abnormal 112 (14.7)
L1CAM positive 79 (10.4)
ER/PR negative 151 (19.8)
Post-operative histology
Tumor grade 1–2 607 (79.6)
3 156 (20.4)
Histology Endometrioid 714 (93.6)
Non-endometrioid 49 (6.4)










Positive (N1) 53 (6.9)
Negative (N0) 440 (57.7)
Unknown† (Nx) 270 (35.4)



















Not classified 2 (1.9)
Mortality Overall 102 (13.4)
EC-related 61 (8.0)
Data is presented in number (%), mean ± standard deviation (SD).
EC, endometrial cancer; ER/PR, estrogen receptor/progesterone receptor; ESMO-ESGO-
ESTRO, European Society for Medical Oncology - European Society of Gynaecological On-
cology - European SocieTy for Radiotherapy & Oncology; EBRT, external beam radiother-
apy; FIGO, Federation International Gynaecology Obstetric; L1CAM, L1 cell-adhesion
molecule; N, number; VBT, vaginal beam therapy.
† No lymphadenectomy performed.
S.W. Vrede, W.J. van Weelden, N.C.M. Visser et al. Gynecologic Oncology 161 (2021) 787–794but not performed in this study cohort. For the relation of IHC bio-
markers and LN status, including the survival analysis, patients with
LN status unknown (Nx) were excluded for analysis.
2.5. Outcome measurements
Our primary aim was to define the added prognostic relevance of
pre-operative IHC biomarkers, p53/L1CAM/ER/PR, to the ESMO-ESGO-
ESTRO risk classification groups in EC. Secondary, the added prognostic
relevance of these IHC biomarkers to LN status in EC.
2.6. Statistical analysis
For statistical analyses, Statistical Package for the Social Sciences
(SPSS), version 25.0 (IBM, New York, NY, USA) was applied. The results
were considered significant if P-value was less than 0.05 (P< 0.05). For
the association of IHC expressionwith the ESMO-ESGO-ESTRO risk clas-
sification groups, the Mantel-Haenszel chi2 test for trend was used.
Survival analyses were performed using the Kaplan Meier curves
(first 10 years after diagnosis) and univariate and multivariate Cox-
regression. Recurrence-free survival (RFS) was defined as time from
surgery to time of recurrence from EC disease, and disease-specific sur-
vival (DSS) was defined as time from date of surgery to date of death
from EC, all censored by date of last contact. The definition of ER/
PR was defined as either ER or PR negative and/or positive. The
ESMO-ESGO-ESTRO risk classification in the survival analysis was di-
chotomized: ‘low, intermediate and high-intermediate’ and ‘high and
advanced/metastatic’. This dichotomy was used, as the ‘high and ad-
vanced/metastatic’ ESMO-ESGO-ESTRO risk classification groups in-
cluded all cases with LNM. Associations were calculated as hazard
ratio (HR)with corresponding 95% confidence interval (CI) and P-value.
2.7. Ethics approval
This studywas approved by the Institutional Review Board Radboud
UniversityMedical Center and the Institutional ReviewBoards of all par-




A total of 1199 patients were included from ten European hospitals.
For the current study only patients with available pre-operative endo-
metrial biopsies were included. Samples with insufficient tumor tissue
were excluded, resulting in 763 patients with a median follow-up of
5.5 years [9]. Baseline patient- and tumor characteristics of included pa-
tients were not significantly different when compared with excluded
patients (data not shown).
Clinicopathological characteristics of the study cohort are shown in
Table 1. Mean patient age in the study population was 65 years. Most
patients presented pre-operatively with low-grade (1–2) EC and
endometrioid histology, 71.4% and 89.4% respectively. Pre-operative
IHC expression of p53-abn was present in 112 (14.7%), L1CAM+ in 79
(10.4%) and ER/PR- in 151 (19.8%) patients. IHC stainingwas unsuccess-
ful in N= 67 cases for p53, N= 19 for L1CAM, N= 1 for ER and N=6
for PR. Lymphadenectomy was performed in 493 (64.6%) patients of
whom 53 (10.7%) patients had LNM (N1). Adjuvant treatment was ad-
ministered in 347 (45.6%) patients, of which 81.6% received radiother-
apy (RT). A total of 105 (13.8%) patients developed recurrent EC
disease and 102 (13.4%) patients died of whom 61 (59.8%) due to EC.
Stratification of the study cohort according to the ESMO-ESGO-
ESTRO risk classification is shown in Table 1. A total of 169 (22.1%) EC
patients were classified as ‘high’ risk.7893.2. Immunohistochemical expression in relation to the ESMO-ESGO-ESTRO
risk classification
In Fig. 1 abnormal IHC expression of p53, L1CAM, ER and PR is shown
in relation to the ESMO-ESGO-ESTRO risk classification groups.
Increased abnormal IHC expression was related to higher risk classifica-
tion groups (P< 0.001), with the highest frequency of p53-abn, L1CAM















ESMO-ESTRO-ESGO risk classification groups
YGYNO 978395
Fig. 1. Abnormal immunohistochemical expression of p53, L1CAM and ER/PR in relation to the ESMO-ESGO-ESTRO risk classification. L1CAM, L1 cell-adhesion molecule; ER/PR, estrogen
receptor/progesterone receptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological Oncology - European SocieTy for Radiotherapy
& Oncology.
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risk classification
The RFS according to the ESMO-ESGO-ESTRO risk groups and IHC ex-
pression of p53, L1CAM and ER/PR in the ESMO ‘high and advanced/
metastatic’ risk group are shown in Fig. 2. The ESMO-ESGO-ESTRO risk
classification group ‘high and advanced/metastatic’ are significantly as-
sociated with poor RFS (p < 0.001) (Fig. 2A). Within the ‘high and ad-
vanced/metastatic’ risk group, patients with abnormal IHC expression
of; p53, L1CAM and ER/PR, p53 and L1CAM, L1CAM and ER/PR, and
only ER/PR have the lowest RFS, compare to patients with abnormalA. B.
Fig. 2. A. RFS for the ESMO-ESGO-ESTRO risk groups. B. RFS for the ESMO-ESGO-ESTRO ‘high an
ESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological On
p53-wildtype; L1CAM, L1 cell-adhesion molecule; ER/PR, estrogen receptor/progesterone rece
790expression of; p53 and ER/PR, only p53 and only L1CAM (Fig. 2B). De-
tailed survival curves of the ESMO-ESGO-ESTRO risk groups in relation
to IHC expression are demonstrated in Fig. 3A-C. Patientswith abnormal
IHC expression (p53-abn, L1CAM+ or ER/PR-) and ESMO-ESGO-ESTRO
risk group ‘high and advanced/metastatic’ show the lowest RFS com-
pared with the other subgroups.
The DSS according to the ESMO-ESGO-ESTRO risk classification
groups, and detailed survival curves of the ESMO-ESGO-ESTRO risk
group in relation to the IHC expression were comparable to the RFS
(SupplementaryFig. S1A and Fig. S2A-C). Within the ESMO ‘high and ad-
vanced/metastatic’ risk group, patients with abnormal IHC expressiond advanced/metastatic’ risk group in relation to p53, L1CAM and ER/PR expression. ESMO-
cology - European SocieTy for Radiotherapy & Oncology; p53abn, p53-abnormal; p53wt,




Fig. 3. A. RFS for ESMO-ESGO-ESTRO risk groups and p53-expression. B. RFS for ESMO-ESGO-ESTRO risk groups and L1CAM-expression C. RFS for ESMO-ESGO-ESTRO risk groups and
ER/PR-expression. ESMO-ESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological Oncology - European SocieTy for Radiotherapy & Oncology;
p53abn, p53-abnormal; p53wt, p53-wildtype; L1CAM, L1 cell-adhesion molecule; ER/PR, estrogen receptor/progesterone receptor; RFS, recurrence-free survival.
S.W. Vrede, W.J. van Weelden, N.C.M. Visser et al. Gynecologic Oncology 161 (2021) 787–794of; p53, L1CAMand ER/PR, p53 and L1CAM, p53 and ER/PR and only ER/
PR have the lowest DSS compare to patients with abnormal expression
of; L1CAM and ER/PR, only p53 and only L1CAM (Supplementary Fig.
S1B).
3.4. Prognostic relevance of immunohistochemical expression in relation to
the ESMO-ESGO-ESTRO risk classification
Multivariate analysis was performed for the prognostic relevance of
IHC expression in relation to the ESMO-ESGO-ESTRO risk classification
groups. The ESMO-ESGO-ESTRO classification ‘high and advanced/791metastatic’ risk was independently associated with reduced RFS (HR
3.11 [CI 1.93–5.02] P < 0.001)(Table 2). P53-abn, ER/PR- and ESMO-
ESGO-ESTRO classification ‘high and advanced/metastatic’ risk were
independently associated with reduced DSS (HR 1.88 [CI 1.00–3.51]
P=0.048, HR 2.74 [CI 1.48–5.07] P=0.001and HR 5.69 [CI 3.03–10.67]
P< 0.001, respectively) (Table 3).
3.5. Immunohistochemical expression in relation to lymph node status
The LN status in relation to abnormal IHC expression (p53-abn,
L1CAM+ or ER/PR-) is shown in Supplementary Fig. S3. LNM was
Table 2
Univariate and multivariate Cox regression analysis of RFS.
Variable Univariate RFS Multivariate RFS
HR 95% CI P-value HR 95% CI P-value
ESMO-ESGO-ESTRO risk classification
‘Low - Intermediate - High-intermediate’ vs ‘High – Advanced/metastatic’ 3.92 2.52–6.08 <0.001⁎ 3.11 1.93-5.02 <0.001⁎
Immunohistochemical markers
p53-abnormal 2.94 1.83–4.72 <0.001⁎ 1.58 0.92-2.71 0.097
L1CAM+ 4.27 2.63–6.92 <0.001⁎ 1.78 0.98-3.21 0.058
ER/PR- 3.16 2.03–4.91 <0.001⁎ 1.54 0.90-2.63 0.115
CI, confidence interval; ER/PR, estrogen receptor/progesterone receptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology-European SocieTy for Radiotherapy & Oncology-
European Society of Gynaecological Oncology; HR, Hazard ratio; L1CAM, L1 cell-adhesion molecule; RFS, Recurrence-free survival.
⁎ p < 0.05.
S.W. Vrede, W.J. van Weelden, N.C.M. Visser et al. Gynecologic Oncology 161 (2021) 787–794observed in 21.4% of p53-abn, 31.3% of L1CAM+, and 20% of ER/PR-
cases. Survival outcome curves (RFS and DSS) of abnormal and normal
IHC expression in relation to LN status (N1/N0) is shown in Supplemen-
tary Fig. S4A-C and Fig. S5A-C. Patients with LNM (N1) and p53-abn or
L1CAM+ had significantly decreased RFS/DSS compared with, patients
having LNM (N1) and normal IHC expression (p53-wt or L1CAM-),
and patients without LNM (N0) and normal/abnormal IHC expression
(p < 0.001). No significant reduction in RFS was seen in patients with
LNM (N1) and ER/PR- compared with patients having LNM (N1) and
ER/PR+ (Supplementary Fig. S4C). Patients with LNM (N1) and ER/PR-
had significantly reduced DSS compared with patients having LNM
(N1) and ER/PR+ (Supplementary Fig. S5C). Patients without LNM
(N0) and abnormal IHC expression (p53-abn, L1CAM+ or ER/PR-) had
similar RFS/DSS compared with patients with LNM (N1) and normal
IHC expression (p53-wt, L1CAM- or ER/PR+) (Supplementary Fig. S4A-
C andFig. S5A-C).4. Discussion
In this study the added prognostic relevance of the pre-operative
IHC expression of p53, L1CAM and ER/PR, to the ESMO-ESGO-ESTRO
risk classification groups is demonstrated. Significantly increased ab-
normal IHC expression is observed in higher risk classification groups.
Within the ‘high and advanced/metastatic’ risk group, patients with a
combination of abnormal IHC expression had the poorest outcome
(RFS and DSS). ER/PR-, p53-abn, and ESMO-ESGO-ESTRO ‘high and ad-
vanced/metastatic’ risk group were independently associated with de-
creased DSS. Furthermore, abnormal IHC expression had added
prognostic relevance to LN status. Patients with abnormal IHC expres-
sion and LNMhadmost dismal outcome. Interestingly, patients without
LNM and abnormal IHC expression showed comparable RFS/DSS to,
patients with LNM and normal biomarkers. This indicated that the IHC
biomarkers p53, L1CAM and ER/PR have prognostic relevance to the
ESMO-ESGO-ESTRO risk classification groups and to patients with and
without LNM.Table 3









CI, confidence interval; DSS, disease-specific survival; ER/PR, estrogen receptor/progesterone re
Radiotherapy & Oncology-European Society of Gynaecological Oncology; HR, Hazard ratio; L1C
⁎ p < 0.05.
792Our findings of p53-abn as important prognosticator is in line with
the TCGA data that have been validated by multiple other research
groups [10,21]. The percentage of p53-abn in our study cohort (12.0%)
in patients with endometroid histology was comparable to the original
TCGA paper (11.4%) [10]. Instead of using p53 sequencing, we used easy
accessible p53 IHC staining comparable to the ProMisE classification
system,whichwas shown to be a good surrogate biomarker for p53mu-
tations [11,13,22]. Talhouk et al. studied the prevalence and prognostic
relevance of p53-abn in the ESMO risk classification, and observed a
high prevalence of p53-abn in the ESMO ‘high’ risk group in line with
our findings [13]. The fact that integration of ProMisE/TCGA in the
ESMO risk classification did not show significant difference in outcome,
is contrary to our results in which p53-abn had added prognostic value
in the ‘high and advanced/metastatic’ risk group. This could be ex-
plained by the use of the ESMO 2013 guideline in the study of Talhouk
et al. compared with the ESMO-ESGO-ESTRO 2016 guideline used in
our study [13].
In addition to p53-abn, L1CAM+ is an established prognosticator in
EC as observed in our study [16,20,23]. The percentage of L1CAM+
cases was slightly lower in our study compared with other studies
[16,19,20,23,24]. This might be related to the fact that pre-operative
analysis was used instead of final tumor sections in which L1CAM can
be expressed focally and/or at the invasive front predominantly [25].
Our results are in line with a study reporting that patients with
L1CAM+ had significantly reduced survival also in the ESMO-ESGO-
ESTRO ‘high and advanced/metastatic’ risk group compared with nor-
mal L1CAM expression [24]. A more recent study reported reduced
overall survival (OS) and progression-free survival (PFS) in patients
with FIGO stage III and L1CAM+when comparedwith L1CAM- patients
[26]. This is in linewith our results since FIGO stage III is included in the
‘high’ risk group.
Multiple studies have investigated ER/PR expression in relation to
outcome in EC reporting conflicting results [18,27,28]. In our study,
ER/PR- was not significantly related to RFS in the multivariate analysis,
contrary to previous studies [18,27,28]. In line with the study by Trovik
et al., ER/PR- was related to DSS and LNM [17]. In a previous ENITECariate DSS Multivariate DSS
95% CI P-value HR 95% CI P-value
3.82–12.57 <0.001⁎ 5.69 3.03-10.67 <0.001⁎
2.56–7.69 <0.001⁎ 1.88 1.00-3.51 0.048⁎
3.19–9.26 <0.001⁎ 1.17 0.59-2.31 0.656
3.30–9.12 <0.001⁎ 2.74 1.48-5.07 0.001⁎
ceptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology-European SocieTy for
AM, L1 cell-adhesion molecule.
S.W. Vrede, W.J. van Weelden, N.C.M. Visser et al. Gynecologic Oncology 161 (2021) 787–794study of our study group, mainly loss of PR predicted disease recurrence
[18]. Biologically, loss of ER is preceded by loss of PR and therefore PR
might be the most relevant to outcome. In the current study, we did
not analyze ER/PR separately, interestingly, loss of PR was mainly pres-
ent in the ‘advanced/metastatic’ risk group, underlining the possible rel-
evance for distant spread. The expression of ER/PR was studied in
relation to the different TCGA groups and although ER and PR bio-
markers were both predictive for outcome in the univariate analysis,
only the ProMisE subtypes maintained significant associated with out-
come in the multivariate analysis. It was suggested that the prognostic
significance of single biomarkers could be explained by being a
covariable with the ProMisE molecular subtype [16]. Similar was
shown in the study of Stelloo et al. [29]. Due to the used cut-offs for
ER/PR of 5% and 1% respectively in one study, the prognostic value
might have been underestimated when compared with the 10% cut-
off that was used in our study and the study by Trovik et al. [16,17].
Stelloo et al. did used the 10% cut-off, however they only included
early stage EEC patients hampering comparison to our study [29].
There is an ongoing debate about routine surgical staging with LN
dissection or sampling in EC, especially after the introduction of molec-
ular profiling. Yet, LN status as determined by either lymphadenectomy
or SLN remains an important prognosticator for survival and guiding ad-
juvant treatment in the current ESMO-ESGO-ESTRO risk classification
[5,30–33]. The study of Ouldamer et al. concluded, that even patients
within the ‘high-intermediate’ risk group should receive systematic
nodal staging for a significant better survival [34]. This is in line with re-
cent paper of Weelden et al. that demonstrated that patients with FIGO
IIIA-B had significant improved outcome if LN were sampled and nega-
tive [35]. Our results show the prognostic relevance of IHC expression in
addition to LN status, similar to other studies [17,19]. The importance of
both, IHC biomarkers and LN status, is shown in our results since pa-
tients with LNM and normal IHC expression had comparable RFS/DSS
to patients without LNM and abnormal IHC expression.
To our knowledge the prognostic relevance of integrating IHC bio-
markers in the ESMO-ESGO-ESTRO risk classification groups has not
been studied so far. Yet, there are some limitations that need to be ad-
dressed. First, in addition to the IHC biomarkers, we did not include
thewell-establishedfinal histopathologicalmarkers related to the prog-
nosis. However, as expected the pre-operative abnormal biomarker ex-
pression of p53, L1CAM and ER/PR are significant associated with grade
3, NEEC, LVSI, MI and cervical stromal invasion (CSI) (data not shown).
Abnormal pre-operative biomarkers could therefore serve as surrogate
biomarkers for these final histopathological risk factors. Second, as we
used p53 IHC expression as indicator for p53-abn without information
on POLE or mismatch repair deficient (MMR-D) status, we might have
slightly overestimated the number of patients with p53-abn. However,
as multiple classifiers are only present in 3% of the cases, it is unlikely
that this has influenced our findings [36]. Finally, inherent to the retro-
spective character of the study, differences in outcome might be ex-
plained by the fact that adjuvant treatment was not uniformly applied.
Themajority (80–100%) of the patientswith LNMand abnormal IHC ex-
pression received chemotherapy (CT) or chemo- and radiotherapy
(CTRT) as adjuvant treatment, compared with 55% for patients with
LNM and normal IHC expression (data not shown). This difference in
percentage could be explained by patients being treated according
final tumor stage and histology in different ENITEC centers in Europe,
i.e. patients that received more often radiotherapy mainly had
endometrioid histology, whereas those with adjuvant chemotherapy
more often non-endometrioid histology. Thus, patients having worst
outcome most frequently received CT or CTRT instead of RT alone, and
this does therefore not explain the specifically worse outcome in these
patients.
The strength of thismulticenter study is the large patient cohort, and
well-documented and long-term follow-up. Although primary and ad-
juvant treatment was not uniformly applied, the current study reflects
actual clinical practice facilitating implementation.793For this studywe focused on the IHC expression in the pre-operative
setting, as the risk of extended disease and LNM appears mainly associ-
ated with p53-abn and significantly less with the other TCGA groups
[12]. We expect that molecular profiling will be incorporated in future
treatment planning [37–40]. The study of Leslie et al. revealed that
patients with TP53 mutation had significant better PFS with adjuvant
chemotherapy + bevacizumab when compared to chemotherapy +
temsirolimus, this significant difference was not shown in patients
with TP53wildtype [41]. This illustrated the relevance of TCGA with re-
spect to the adjuvant treatment. However, routinemolecular analysis is
expensive and requires fully equipped laboratory, therefore a step-wise
approach could bridge this gap, and contribute to selective molecular
profiling in ‘high’ risk EC patients [13]. Cosgrove et al. showed that
even selective molecular profiling in patients with only EEC histology
could provide additional prognostic information. This step-wise ap-
proach could be used combined with the Lynch syndrome screening
panel and so refining the choice of adjuvant treatment [42]. The recently
published ENDORISKmodel demonstrates that pre-operative identifica-
tion for patients at risk for LNM can be significantly improved by incor-
porating clinical and IHC biomarkers into a Bayesian network [9].
Although we fully endorse the integration of both clinical and IHC bio-
markers, in clinical practice we often have to deal with incomplete
data. This current study showed that the IHC biomarkers could serve
as indicator for LNdirected surgery and either IHC biomarkers ormolec-
ular profiling or a combination, could be used as refinement for selective
adjuvant treatment by being incorporated in the ESMO-ESGO-ESTRO
risk classification and being used next to LN status. These results should
be further validated in anprospective studywithan independent cohort.
5. Conclusion
Concluding, pre-operative IHC biomarkers are important prognostic
markers within the ESMO-ESGO-ESTRO risk classification groups and
in addition to LN status. For daily clinical practice, integrating IHC
expression of p53/L1CAM/ER/PR into the ESMO-ESGO-ESTRO risk
classification groups may be valuable in guiding surgical staging,
and identifying patients who would benefit from specific adjuvant
treatment.
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